Literature DB >> 15525793

Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation.

So Youn Park1, Jeong Hyun Lee, Yong Ki Kim, Chi Dae Kim, Byung Yong Rhim, Won Suk Lee, Ki Whan Hong.   

Abstract

This study shows cilostazol effect to prevent remnant lipoprotein particle (RLP)-induced monocyte adhesion to human umbilical vein endothelial cells (HUVECs). Upon incubation of HUVECs with RLP (50 microg/ml), adherent monocytes significantly increased by 3.3-fold with increased cell surface expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1, E-selectin, and monocyte chemoattractant protein-1 (MCP-1). Cilostazol ( approximately 1-100 microM) concentration dependently repressed these variables as did (E)3-[(4-t-butylphenyl)sulfonyl]-2-propenenitrile (BAY 11-7085) (10 microM), a specific nuclear factor-kappaB (NF-kappaB) inhibitor. Cilostazol effects were significantly antagonized by iberiotoxin (1 microM), a maxi-K channel blocker. RLP significantly increased expression of lectin-like receptor for oxidized low-density lipoprotein (LDL) (LOX-1) receptor protein. Upon transfection with antisense LOX-1 oligodeoxynucleotide (As-LOX-1), LOX-1 receptor expression was reduced, whereas HUVECs with sense LOX-1 oligodeoxynucleotide did express high LOX-1 receptor. RLP-stimulated superoxide and tumor necrosis factor-alpha levels were significantly lowered with decreased expression of VCAM-1 and MCP-1 by transfection with As-LOX-1 as did polyinosinic acid (10 microg/ml, a LOX-1 receptor inhibitor). RLP significantly degraded inhibitory kappaBalpha in the cytoplasm and activated nuclear factor-kappaB (NF-kappaB) p65 in the nucleus of HUVECs with increased luciferase activity of NF-kappaB, all of which were reversed by cilostazol (10 microM), BAY 11-7085, and polyinosinic acid. Together, cilostazol suppresses RLP-stimulated increased monocyte adhesion to HUVECs by suppression of LOX-1 receptor-coupled NF-kappaB-dependent nuclear transcription via mediation of the maxi-K channel opening.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525793     DOI: 10.1124/jpet.104.077826

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study.

Authors:  Heidi T May; John R Nelson; Seth T Lirette; Krishnaji R Kulkarni; Jeffrey L Anderson; Michael E Griswold; Benjamin D Horne; Adolfo Correa; Joseph B Muhlestein
Journal:  Eur J Prev Cardiol       Date:  2015-10-19       Impact factor: 7.804

Review 2.  Extracellular vesicles and atherosclerotic disease.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Cell Mol Life Sci       Date:  2015-04-17       Impact factor: 9.261

Review 3.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

Review 4.  Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.

Authors:  Bai-Hui Zhang; Fan Yin; Ya-Nan Qiao; Shou-Dong Guo
Journal:  Front Mol Biosci       Date:  2022-05-25

5.  Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.

Authors:  Limin Wang; Rajan Gill; Theresa L Pedersen; Laura J Higgins; John W Newman; John C Rutledge
Journal:  J Lipid Res       Date:  2008-09-23       Impact factor: 5.922

6.  Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells.

Authors:  So Youn Park; Jeong Hyun Lee; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Byung Yong Rhim; Yung Woo Shin; Ki Whan Hong
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

7.  Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis.

Authors:  S Y Park; S W Lee; S H Baek; C W Lee; W S Lee; B Y Rhim; K W Hong; C D Kim
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 8.  Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

Authors:  Jeong Hyun Lee; So Youn Park; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Ki Whan Hong
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 9.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

10.  Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits.

Authors:  Hideki Ito; Kenji Uehara; Yutaka Matsumoto; Ayako Hashimoto; Chifumi Nagano; Manabu Niimi; Goro Miyakoda; Keisuke Nagano
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.